Figure (Bortezomib 01)
Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 72338-200
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 72338-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Waverley Pharma Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure (Bortezomib 02)
This text provides a formula for calculating the total volume of Bortezomib for Injection to be administered based on the dose in milligrams per square meter (mg/m^2) and the patient's Body Surface Area (BSA) in square meters (m^2). The calculation involves multiplying the dose by the BSA to determine the total volume in milliliters (mL) to be administered. The concentration of the Bortezomib for Injection solution is specified as 2.5 mg/mL.*
Chemical Structure (Bortezomib 03)
Figure 1 (Bortezomib 04)
Figure 2 (Bortezomib 05)
This text seems to contain data related to the percentage of patients at risk over a certain period of time. The numbers provided appear to represent the number of patients at risk for different treatment groups at various time points in months. The information also indicates the percentage of patients remaining after the indicated time point and references p-values from logrank test. This data is likely part of a medical or scientific study or report.*
Figure 3 (Bortezomib 06)
This text provides data on the proportion of patients over time who received Bortezomib and Doxamethasone as part of a study. The statistical significance is also mentioned with a p-value below 0.00017. The number of patients at different time points is shown, along with the p-value from a log-rank test.*
Figure 4 (Bortezomib 07)
This text provides information on the proportion of patients who received Bortezomib and Dexamethasone in a study. The data includes the number of patients remaining at different time points for each treatment group and the p-value from the log-rank test. The results suggest a statistically significant difference (p<0.05) between the two treatment groups.*
Figure 5 (Bortezomib 08)
Figure 6 (Bortezomib 09)
Principal Display Panel (3.5 mg Vial Label)
Description: This text provides details about a medication with the code "MH/DRUGS/28-KD/476." It contains a lyophilized vial of bortezomib and mannitol for injection. The usual dosage information can be found in the package insert. The storage instructions indicate keeping it at 25°C with excursions permitted between 15°C and 30°C. The medication is a cytotoxic agent made in India. It is a single-dose vial that should be discarded if unused. Additional caution is advised to protect it from light. The manufacturer is mentioned as Modicurs Pharma, Inc. from Princeton, NJ, USA.*
Principal Display Panel (3.5 mg Vial Carton)
This text provides detailed information about a medication called Bortezomib, which is intended for injection. It includes instructions on reconstitution, storage, dosage, and cautions related to its use as a cytotoxic agent. The product contains 3.5 mg of bortezomib and 35 mg of mannitol. It specifies single-dose vial usage and gives information on temperature storage requirements. The medication is for subcutaneous or intravenous injection only. Additionally, it includes details on the company distributing the product and mentions that it is made in India.*
Principal Display Panel Inside Flap (all Cartons) (Bortezomib 13)
This text describes the use of Bortezomib for Injection via subcutaneous and intravenous administration. It provides details about the recommended concentrations, volumes, and sodium chloride solution to be used. Instructions are given on placing stickers on the vial and syringe for proper dosage administration. Additionally, it refers to the package insert for comprehensive instructions on administering Bortezomib for Injection.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
